Fortis Healthcare profits climb 31% on double-digit revenue growth

What's new with Fortis Healthcare Ltd.

• FY26 consolidated revenue grew 17.3% to ₹9,128 crore.
• Hospital segment revenue rose 19.1%, while diagnostics revenue climbed 8.5%.
• Board recommends a final dividend of ₹1 per share.

Why this matters for Fortis Healthcare Ltd.

The results show sustained momentum across Fortis’s core hospital and diagnostic businesses. With operating EBITDA margins expanding, the company is successfully converting top-line gains into bottom-line profit growth.

What we're watching

• Sustainability of margin improvements in the diagnostic division.
• Updates on capacity expansion plans following a strong fiscal year.
• Any further guidance on future capital allocation policies.

The full read

Fortis Healthcare ended FY26 with a **31.5%** jump in net profit to **₹1,064 crore**. Consolidated revenue reached **₹9,128 crore**, representing a **17.3%** expansion over the year.

Growth is widespread.

The core hospital business provided the primary engine, rising **19.1%** to **₹7,773 crore**, while the diagnostics arm grew more modestly at **8.5%** to **₹1,527 crore**. Because operating EBITDA margins improved across both segments simultaneously, the firm successfully converted its top-line gains into bottom-line profit growth. The board confirmed this fiscal performance with a recommended final dividend of **₹1** per share and a clean, unmodified audit opinion. This is a predictable, steady result for a large-cap player in the healthcare space. The filings contain no strategic shocks, confirming that Fortis is simply sticking to its current operational trajectory. The test remains whether these margin gains hold as the firm continues to scale its hospital bed capacity nationwide.